PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation by Ngo, Greg et al.
Oncotarget37549www.oncotarget.com
PARP inhibition prevents escape from a telomere-driven crisis 
and inhibits cell immortalisation 
Greg Ngo1, Sam Hyatt1, Julia Grimstead1, Rhiannon Jones1, Eric Hendrickson2, 
Chris Pepper3 and Duncan Baird1
1Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
2Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, USA 
3University of Sussex, Brighton and Sussex Medical School, Brighton, UK 
Correspondence to: Duncan Baird, email: bairddm@cardiff.ac.uk
Keywords: telomere; genome instability; PARP1; crisis; cancer
Received: August 19, 2018    Accepted: December 10, 2018    Published: December 25, 2018
Copyright: Ngo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Telomeric crisis is the final replicative barrier to cell immortalisation; it is 
characterised by genome instability and cell death and is triggered when telomeres 
become critically short and are subjected to fusion. Pre-cancerous lesions, or early 
stage cancers, often show signs of a telomere crisis, suggesting that escape from 
telomere crisis is a prerequisite for disease progression. Telomeric crisis therefore 
represents an attractive, and as yet unexplored, opportunity for therapeutic 
intervention. Here, we show that two clinically approved PARP inhibitors, selectively 
eliminate human cells undergoing a telomere-driven crisis. Clonal populations of 
a colorectal cancer cell line (HCT116), or the plasma cell leukaemia cell line (JJN-
3), expressing a dominant-negative telomerase, entered a telomere-driven crisis at 
defined population doubling points and telomere lengths. The addition of the PARP 
inhibitors, olaparib or rucaparib prevented these cells from escaping crisis. PARP 
inhibition did not alter cellular proliferation prior to crisis, rates of telomere erosion 
or the telomere length at which crisis was initiated, but affected repair of eroded 
telomeres, resulting in an increased in intra-chromosomal telomere fusion. This was 
accompanied by enhanced DNA damage checkpoint activation and elevated levels 
of apoptosis. We propose that PARP inhibitors impair the repair of dysfunctional 
telomeres and/or induce replicative stress at telomeres to inhibit escape from a 
telomere crisis. This is the first demonstration that a drug can selectively kill cells 
experiencing telomeric crisis. We propose that this type of drug, which we term 
‘crisolytic’, has the potential to eliminate pre-cancerous lesions and tumours exhibiting 
short dysfunctional telomeres.
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INTRODUCTION
Telomeres are nucleoprotein structures that protect 
the ends of linear eukaryotic chromosomes. In humans, 
telomeres are composed of single and double-stranded 
TTAGGG repeats that are bound by the telomere 
capping complex, Shelterin [1]. The primary function of 
telomeres is to prevent the activation of the DNA damage 
response by shielding the end of chromosomes from 
being recognised as DNA strand breaks [2]. Due to the 
end replication problem, telomeres in most somatic cells 
in humans become progressively shortened with each 
cell division. The process of telomere erosion eventually 
leads to sequential activation of two cellular states called 
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senescence and crisis, which limit cell proliferation [3]. 
Senescence is a cell cycle arrest state, which is triggered 
when short telomeres partially lose their end-protective 
function and activate the DNA damage checkpoint 
machinery [4]. This proliferative block can be bypassed 
by mutations in the TP53 pathway, which permits further 
cell division and telomere erosion [5]. This, in turn, leads 
to the onset of crisis, which is characterised by genome 
instability and cell death and is triggered when telomeres 
become critically short and are subjected to DNA repair 
activity resulting in telomere fusion [6].
Genome instability induced during telomere 
crisis is considered to drive clonal evolution and cancer 
progression [1]. Pioneering studies using telomerase null 
mice showed that telomere crisis induces non-reciprocal 
translocations that promote cancer progression in these 
mice [7, 8]. Telomere erosion and crisis are associated 
with the initiation of various malignancies in humans 
[9–13]. Furthermore, the telomere length of tumour cells 
can accurately predict the progression of both solid and 
haematological cancers [14–16]. The clear requirement 
for cells to escape from telomere crisis and establish 
replicative immortality during tumour progression is 
supported by the finding that all cancer cells activate 
telomerase, or the alternative lengthening of telomeres 
(ALT) pathway, to facilitate ongoing proliferation 
[3, 17]. These findings indicate that interventions that 
could modulate the ability of cells to escape a telomeric 
crisis, or specifically sensitize cells with short telomeres to 
therapy, could represent a promising alternative treatment 
strategy in the earliest stages of tumour progression.
HCT116 cells (a human colorectal cancer cell 
line) undergoing a telomeric crisis require the activity of 
DNA ligase III (LIG3), but not DNA ligase IV (LIG4) 
to escape a telomere crisis [18]. The reason for this 
requirement is not completely understood, but LIG3 is 
believed to be needed for alternative non-homologous 
end-joining (A-NHEJ), whereas LIG4 promotes classical 
non-homologous end-joining (C-NHEJ) [19]. PARP1, 
a DNA repair protein that catalyses the process of poly-
ADP-ribosylation (PARylation), promotes A-NHEJ with 
LIG3 [20, 21]. PARP1 is recruited to various types of 
DNA damage and acts by cleaving NAD+ to nicotinamide 
and ADP-ribosyl moieties, which are successively used to 
synthesise covalently linked ADP-ribose chains on target 
proteins [22]. 
PARPi (PARP inhibitors) are a class of small 
molecule inhibitors developed to inhibit the process 
of poly-ADP-ribosylation by PARP1. Most PARPi are 
nicotinamide mimics that bind into the NAD+ pocket 
of PARP1 thereby inhibiting its PARylation activity 
[23]. Importantly, PARPi potentiate the cytotoxicity of 
various chemotherapeutic agents suggesting that their 
mechanism of action is distinct and complementary to 
existing treatments [23]. In 2005, two landmark studies 
showed that PARPi selectively killed breast cancer allele 1 
or breast cancer allele 2 (BRCA1/BRCA2)-deficient 
cancer cells by inducing the collapse of replication forks 
[24, 25]. This finding paved the way for PARPi to be used 
as a monotherapy agent to kill BRCA1/BRCA2-deficient 
cancer cells and other cancerous cells that share molecular 
features with BRCA1/BRCA2-deficient tumours [26]. 
Following some positive clinical trials, two PARPi, 
rucaparib and olaparib, have been clinically approved for 
the treatment of ovarian cancer [23].
In this study, we examined whether PARPi affect 
the ability of human cells to escape a telomere crisis. 
We found that two clinically approved PARPi, olaparib 
and rucaparib, prevent human colorectal cancer cells and 
cancerous plasma cells from escaping telomere crisis and 
establishing replicative immortality. Our data indicate 
that PARPi selectively kills cells undergoing a telomere 
crisis by affecting the repair of eroded telomeres and thus 
increasing DNA damage and apoptosis.
RESULTS
Olaparib and rucaparib inhibit HCT116 
dominant negative human telomerase (DN-
hTERT)-expressing cells from escaping a 
telomere crisis
To study the effect of PARP inhibition during a 
telomere-driven crisis, we used a TP53-positive HCT116 
colorectal cancer cell line expressing a DN-hTERT 
construct. Telomerase activity is abrogated in these cells 
and they show progressive telomere erosion as a function 
of cell division. After 55 population doublings (PDs) 
from the point of single-cell cloning, these cells entered a 
telomere erosion-induced crisis-like state, characterised by 
slowed cell growth, increased apoptosis and the induction 
of telomere fusion events [18]. After approximately 30 
days in crisis, the HCT116 DN-hTERT clones reproducibly 
escaped crisis and become (re)-immortalised, following the 
re-establishment of telomerase activity, the lengthening of 
telomeres and the cessation of telomere fusions [18].
To understand whether PARPi could affect the 
ability of an HCT116 DN-hTERT clone to escape a 
telomere crisis, we cultured these cells in a range of 
concentrations of olaparib (0.05 µM, 0.1 µM, 0.5 µM, 
1 µM and 5 µM) starting at PD33 — 22 PDs before 
these cells were expected to enter crisis. We chose this 
concentration range because at least 1 µM of olaparib is 
required to fully inhibit PARP1 activity in HCT116 cells 
[27]. Another previous study showed that 0.4 µM of 
rucaparib effectively inhibited PARP activity in SW620 
colorectal cancer cells for up to 3 days [28]. Thus, to 
ensure that PARP1 remained inhibited, new drug was 
added to the cells every 3 days. As controls, we also 
examined untreated cells and those treated with dimethyl 
sulfoxide (DMSO, the vehicle). Consistent with our 
previous findings [18], untreated HCT116 DN-hTERT 
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cells (PD33) underwent an additional 22 PDs before 
entering crisis, characterised by slow cell growth and the 
appearance of large vacuolated cells (Figure 1A, data not 
shown). After approximately 30 days in crisis, some cells 
escaped crisis and continued to divide at the same rate as 
that observed prior to crisis, continuing to over 100 PD 
when the experiment was intentionally terminated.
Cells treated with DMSO or low concentrations of 
olaparib (0.05 µM, 0.1 µM and 0.5 µM) behaved similarly 
to the untreated cells, as these cells entered crisis at about 
the same time (PD55, day 56) and all managed to escape 
with the 0.5 µM-treated cells lagging slightly behind the 
lower concentrations and controls (Figure 1A). Cells 
treated with 1 µM of olaparib initially behaved similarly 
to the control cells, dividing at the same rate and entering 
crisis at the same PD point. In striking contrast however, 
despite keeping these cultures for up to 126 days, all of 
the cells eventually died and (per force) no cells managed 
to escape crisis (Figure 1A). Moreover, cells treated with 
5 µM olaparib only managed to divide up to PD44 but 
then stopped dividing and died.
To confirm the effect of PARPi on the escape from 
a telomere-driven crisis, we tested an additional PARPi, 
rucaparib. We examined whether a shorter exposure 
to PARPi could prevent escape from crisis by adding 
rucaparib to HCT116 DN-hTERT cells at a time point 
closer to the onset of crisis. To do this, we added the 
same range of concentrations of rucaparib to HCT116 
DN-hTERT cells at PD46 and PD52 (9 and 3 PDs prior to 
crisis, respectively; Figure 1B, 1C). It was clear from these 
data that even short-term exposure of HCT116 DN-hTERT 
cells to high concentrations of rucaparib (1 µM and 5 µM) 
was also sufficient to prevent these cells from escaping a 
telomere-driven crisis (Figure 1B, 1C). We concluded that 
treatment of HCT116 DN-hTERT cells with PARPi prior 
to the point at which the cells enter crisis was sufficient to 
prevent these cells from escaping crisis.
We next considered whether the effect of olaparib 
and rucaparib on the ability of HCT116 DN-hTERT cells 
to escape crisis was specifically a consequence of telomere 
erosion, or whether this effect might have arisen because 
of impaired cell growth kinetics in the long-term presence 
of PARPi. To assess this, we tested how both olaparib and 
rucaparib affected the growth rates of HCT116 cells that 
did not express DN-hTERT (Supplementary Figure 1). 
We found that only cells treated with 5 µM of olaparib 
or rucaparib exhibited slightly slower growth (0.74 PD/
day and 0.80 PD/day, respectively) than all other treatment 
conditions and controls (untreated controls = 0.96 PD/
day), but even these cells managed to propagate for over 
52 PD at which point all the cultures were intentionally 
terminated (Supplementary Figure 1). We therefore 
concluded that high dose and short-term exposure of 
PARPi can selectively eliminate HCT116 DN-hTERT cells 
undergoing a telomere-driven crisis and prevent these cells 
from becoming immortalised and that this effect is not 
related to a general inhibition of proliferation.
Rucaparib and olaparib inhibit JJN3 DN-
hTERT cells from escaping a telomere crisis
To further test the effect of PARPi on telomere 
crisis, we examined the p53-null multiple myeloma 
cell line, JJN-3 [29]. To induce a telomere crisis, we 
transfected JJN-3 cells with a DN-hTERT construct and 
analysed how this affected the proliferation of three 
individual JJN-3 clones (Figure 2A). After 25 to 30 
PDs, each clone experienced a period of stalled growth, 
before eventually recovering and growing steadily until 
the experiments were terminated (Figure 2A). We next 
examined telomerase activity in these clones and found 
that while telomerase activities were low before the slow 
growth period, all three clones had significantly higher 
activity of telomerase after they had recovered, indicating 
that these cells had been re-immortalised (Figure 2B). 
Examination of telomere length distributions using 
STELA and telomere fusion using single-molecule PCR 
[30] confirmed that JJN-3 DN-hTERT cells had short 
telomeres and increased telomere fusions during the slow 
growth period, but that their telomeres were elongated and 
stabilized (as shown by a reduction of telomere fusions) 
after escape (Supplementary Figure 2). These data are 
consistent with the JJN-3 DN-hTERT clones transiting 
a telomere erosion-induced crisis followed by eventual 
escape and re-immortalisation.
To examine whether PARPi affected the ability of 
JJN-3 DN-hTERT cells to escape a telomere crisis, we 
split a clonal JJN-3 DN-hTERT population (clone B) into 
twelve subpopulations before the onset of crisis (PD23), 
and cultured the cells in 1.0 μM, 2.5 μM, 5.0 μM and 
7.5 μM of rucaparib, or, 0.5 μM. 1.25 μM, 2.5 μM and 
3.75 μM of olaparib (Figure 2C, 2D). We also included 
untreated and DMSO-treated controls for each experiment. 
As expected, the untreated JJN-3 DN-hTERT cells entered 
crisis at around PD29 (day 42) and escaped after 17 days 
(day 59) to continue proliferating until PD53, when the 
experiments were terminated (Figure 2C). DMSO and 
low concentrations (1.0 μM and 2.5 μM) of rucaparib 
did not inhibit JJN-3 DN-hTERT cells from escaping 
crisis. However, cells treated with 5.0 μM and 7.5 μM of 
rucaparib failed to escape, managing only to divide up to 
PD33 and PD28, respectively (Figure 2C). These results 
were mirrored upon treatment with olaparib, where the 
highest concentrations used, 2.5 μM and 3.75 μM were 
sufficient to prevent JJN-3 DN-hTERT cells from escaping 
crisis (Figure 2D). We concluded that high concentrations 
of PARPi prevent JJN-3 DN-hTERT as well as HCT116 
DN-hTERT cells from escaping crisis.
To confirm that the effects of PARPi on JJN-3 
DN-hTERT cells were due to telomere dysfunction, we 
exposed a JJN-3 control population (transfected with an 
empty vector) to the same concentrations of rucaparib 
or olaparib for a similar period of time (Supplementary 
Figure 3). This control clone did not express DN-hTERT 
and so maintained its telomere length above that which 
Oncotarget37552www.oncotarget.com
could lead to a telomere-driven crisis. We observed that 
both rucaparib and olaparib slowed the rate of growth 
of JJN-3 cells (from 0.73 PD/day in the DMSO control 
to 0.42 PD/day in 7.5 μM rucaparib and 0.34 PD/day in 
3.75 μM olaparib), but even at these concentrations JJN-
3 cells were able to be propagated for up to 46 PDs and 
42 PDs, respectively, at which point all the cultures were 
terminated. Overall, these results demonstrate that PARPi 
can inhibit human cells derived from both solid (HCT116) 
and haematological (JJN-3) malignancies from escaping a 
telomere crisis.
PARPi do not affect the rate of telomere erosion 
but increase intra-chromosomal fusion in 
HCT116 DN-hTERT cells 
We next examined whether PARPi affect telomere 
dynamics during crisis. To do this, four independent 
Figure 1: PARPi prevent HCT116 cells from escaping telomere crisis. (A–C) Growth curve of HCT116 DN-hTERT cells 
treated with the indicated concentrations of olaparib and rucaparib (PD = population doubling). Frozen HCT116 DN-hTERT cells at a 
required PD were thawed and propagated before each PARPi was added at the time indicated. Media/drug were replaced at least once every 
three days until the termination of the experiments. 
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HCT116 DN-hTERT cultures treated with 1 µM rucaparib 
were compared with four cultures treated with DMSO. We 
added rucaparib or DMSO to the cells at PD33 (~22 PDs 
prior to crisis) and analysed telomere length distributions 
using STELA and telomere fusion using single-molecule 
PCR [30]. As we observed previously, cells treated with 1 
µM rucaparib grew at a similar rate (0.72 PD/day) as the 
DMSO control cells (0.78 PD/day) and they entered crisis 
at approximately the same PD (~PD53) and time point as 
the DMSO controls, but whilst all the DMSO-treated cells 
escaped crisis, none of the cell cultures treated with 1 µM 
rucaparib managed to survive (Figure 3A).
The telomere length distributions and fusions 
were examined in these cultures at PD33 (before crisis), 
PD59 (crisis), and (where possible) PD82 (escaped from 
crisis). As expected, telomere erosion was observed 
from an average length of 1.91 kb down to 1.53 kb prior 
to crisis (Figure 3B) and telomere fusions between the 
XpYp, 17p and 21q family telomeres was only detected 
during crisis (Figure 3C). Following the escape from 
crisis, the telomeres were elongated to an average length 
of 2.22 kb (Figure 3B); the telomere length distributions 
became more heterogeneous and the telomeres were 
stabilised as very few fusions could be detected in the 
post-crisis cells (PD82; Figure 3C). Thus, the telomere 
length and fusion profiles observed here are consistent 
with our previous observations of HCT116 DN-hTERT 
cells transiting a telomere erosion-induced crisis and 
escape following the re-establishment of telomerase 
activity [18].
Figure 2: PARPi prevent JJN-3 cells from escaping telomere crisis. (A) Growth curve of three clonal populations of JJN-3 cells 
expressing DN-hTERT (PD = population doubling). (B) Telomerase activity of each JJN-3 clonal population was monitored before and 
after crisis and plotted as total product generated (TPG). Significance was determined using a paired t-test. (C, D) Growth curve of JJN-3 
DN-hTERT cells treated with the indicated concentrations of olaparib and rucaparib. Each PARPi was added at the time indicated, and 
media/drug replaced at least once every three days until the termination of the experiments. 
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We next assessed whether PARPi affected the rates 
of telomere erosion. We compared telomere length of 
DMSO- or rucaparib-treated cells at the point that the 
rucaparib-treated cells entered crisis (~PD53), 28 days 
(~20 PDs) after the addition of PARPi (Figure 3D). The 
telomeres of both group of cells were equally short and 
rucaparib did not have any significant impact on telomere 
length (p = 0.59, Mann–Whitney U Test). We concluded 
that PARPi do not affect telomere dynamics or impact on 
the ability of cells to escape telomere crisis by increasing 
the rate of telomere erosion.
Our previous study indicated that the relative 
proportions of the inter-chromosomal, compared to 
intra-chromosomal telomere fusions, may impact on the 
ability of cells to escape crisis, with cells that exhibit a 
greater proportion of inter-chromosomal events being 
compromised in their ability to escape crisis, for example 
as observed in the context of LIG3-deficient cells [18]. To 
examine whether PARPi impacted the relative proportions 
of inter- and intra-chromosomal fusions, we compared 
the fusion of telomeres in cells treated with rucaparib 
or DMSO in our HCT116 DN-hTERT cells undergoing 
Figure 3: PARPi do not affect telomere erosion in HCT116 DN-hTERT cells during telomere crisis. (A) Growth curve of 
HCT116 DN-hTERT cells treated with DMSO or 1µM of rucaparib. DMSO/rucaparib were added at the time indicated, and media/drug 
replaced at least once every three days until the termination of the experiment (PD = population doubling). (B) 17p STELA of HCT116 
DN-hTERT cells (DMSO 3) at PD33 (before crisis), PD59 (crisis), and PD82 (escaped from crisis) (C) Telomere fusion analysis of 
HCT116 DN-hTERT cells (DMSO 3) at PD33 (before crisis), PD59 (crisis), and PD82 (escaped from crisis) using 17p, XpYp and 21q 
family telomere primers. Telomere fusion products were detected with a 17p telomere adjacent probe. (D) STELA of the 17p telomeres 
from cells treated with DMSO or 1 µM rucaparib at the indicated PD (p = 0.59, Mann–Whitney U Test, n = 3). 
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a telomere-driven crisis. We targeted the fusion assay 
to the XpYp and 17p telomeres, which allows inter- and 
intra-chromosomal fusion to be distinguished. At PD 48 
to 49 (three weeks after the addition of PARPi/DMSO), 
we found evidence of both intra- (17p:17p) and inter- 
(17p:XpYp) chromosomal telomere fusion events and 
the total number of fusion is not significantly different 
between PARPi or DMSO treated cells (Figure 4A, 4C). 
However in contrast to that observed in the absence 
of LIG3 [18], there was a significant increase in intra-
chromosomal 17p:17p fusion (96% vs 71%), accompanied 
by a reduction in inter-chromosomal 17p:XpYp fusion 
(4% vs 29%) in cells treated with PARPi (p = 0.005) 
(Figure 4A, 4D).
To further confirm this result, we examined 
telomere fusions in these cells at a later passage (PD 53 
to 54) when the cells were deeper in crisis. As expected, 
we observed increased numbers of both 17p:17p and 
17p:XpYp telomere fusion events in both the DMSO- and 
rucaparib-treated cells, as more telomeres were short and 
dysfunctional at this sampling point (Figure 4B, 4C). The 
total number of telomere fusion was reduced in PARPi 
treated cells compared to DMSO treated cell from 34 to 
25 (p = 0.009) showing that PARPi affect fusion frequency 
deeper in crisis (Figure 4C). Consistent with the results 
in Figure 4A, rucaparib-treated cells displayed elevated 
intra-chromosomal 17p:17p fusion (86% vs 78%) and 
fewer inter-chromosomal 17p:XpYp fusion events (14% 
vs 22%) (p = 0.043; Figure 4B, 4D). Interestingly, the 
level of intra-chromosomal fusion significantly decreased 
(from 96% to 86%, p = 0.023, Figure 4D) in PARPi treated 
cells as these cells progressed through crisis, whereas 
the fusion spectrum was not significantly different in 
control cells between early and late passage (p = 0.277, 
Figure 4D). This observation suggests that some intra-
chromosomal fusions elevated in PARPi treated cells may 
be deleterious, causing these cells to die thus reducing 
the number of total fusions observed in PARPi treated 
cells at late passage (Figure 4C). We concluded that the 
changes in the telomere fusion profiles observed in the 
context of PARPi were distinct from those observed in 
the absence of LIG3, which exhibited increased inter-
chromosomal fusions [18]. Instead, PARPi treated cells 
displayed increased intra-chromosomal fusion which may 
be harmful to these cells.
PARPi enhance DNA damage checkpoint 
activation and apoptosis in cells experiencing a 
telomere crisis 
To further understand the effect of PARPi on cells 
undergoing a telomere-driven crisis, we also monitored 
the cell-cycle distribution of HCT116 DN-hTERT cells 
progressing through crisis in the presence of 1 µM 
rucaparib or DMSO (Figure 5A). As these cells progressed 
towards crisis, there was an increased accumulation 
of cells with a 4N or 8N DNA content (Figure 5A), 
supporting the observation that telomere damage induces 
tetraploidisation [31, 32]. Interestingly, rucaparib treatment 
significantly increased the proportion of cells with a 4N or 
8N DNA content (Figure 5A and Supplementary Figure 4, 
p < 0.05 and p < 0.001 respectively, Student’s T test), 
suggesting that PARPi stimulate G2/M cell-cycle arrest 
in cells experiencing telomere crisis. As controls, we also 
examine HCT116 WT cells growing in the presence of 
1 µM rucaparib or DMSO for a similar length of time 
(Supplementary Figure 5). We found that rucaparib did 
not strongly affect cell cycle progression in HCT116 WT 
cells (Supplementary Figure 5). We considered that the 
G2/M cell-cycle arrest observed in HCT116 DN-hTERT 
cells treated with rucaparib may be due to an enhanced 
DNA damage checkpoint response in cells experiencing a 
telomere crisis. To test this hypothesis, we examined the 
activation of CHK1, CHK2 and p53, which are three of 
the central DNA damage checkpoint effectors. HCT116 
DN-hTERT cells at the onset of crisis (PD56) were 
exposed to 1 µM or 5 µM of rucaparib or olaparib and the 
phosphorylation of CHK1, CHK2 and p53 were monitored 
by western blot (Figure 5B). We also examined the level 
of PARylated proteins to confirm the activity of PARPi 
in these cells. As controls for DNA damage checkpoint 
activation, we included HCT116 wild type (WT) cells 
either not experiencing a telomere crisis (i.e., untreated) 
or cells treated with bleomycin (B) for 24 hr.
HCT116 DN-hTERT cells displayed high levels of 
PARylated proteins as shown by a smear detected with 
a PAR antibody (Figure 5B, lane 1). Consistent with the 
role of olaparib and rucaparib in inhibiting PARylation, 
both these drugs strongly reduced the level of detectable 
PARylated proteins (Figure 5B, compare lane 1 with lanes 
2 to 5). As expected, bleomycin strongly activated the 
DNA damage response in WT HCT116 cells as CHK1, 
CHK2 and p53 were all heavily phosphorylated at their 
DNA damage induced phosphorylation sites (Figure 5B, 
compare lanes 6 and 7). Interestingly, both olaparib and 
rucaparib stimulated the phosphorylation of CHK1 and 
p53 in HCT116 DN-hTERT cells in crisis (Figure 5B, 
compare lane 1 with lanes 3 and 5), but no differences 
in CHK2 phosphorylation status were observed. We also 
examined the effect of PARPi in HCT116 WT cells and 
found that olaparib and rucaparib did not strongly activate 
CHK1 and p53 in these cells (Supplementary Figure 6). 
We concluded that PARPi synergise the DNA damage 
checkpoint activation by activating CHK1 and p53 in cells 
experiencing a telomere crisis.
As aberrant DNA damage checkpoint activation 
can stimulate apoptosis and cell death during a telomere-
induced crisis, we next examined whether PARPi-induced 
DNA damage checkpoint activation enhanced apoptosis in 
HCT116 DN-hTERT cells. We used an Annexin V-PI assay 
to monitor apoptosis in WT HCT116 and HCT116 DN-
hTERT cells which had been treated with 1 µM or 5 µM 
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Figure 4: PARPi increases intra-chromosomal telomere fusion. (A, B) XpYp:17p fusion analysis of HCT116 WT DN-hTERT 
cells treated with DMSO or 1 µM rucaparib at the indicated population doubling (PD). Telomere fusion were amplified using 17p and 
XpYp primers and detected with 17p or XpYp probes indicated on the right. Fusion bands detected with both probes are inter-chromosomal 
17p: XpYp events (a few examples are indicated by arrows), whereas fusion detected with 17p probe only are intra-chromosomal 17p:17p 
events. (C, D) Bar chart showing quantification of total telomere fusion (C) or inter-chromosomal and intra-chromosomal fusion (D) in 
cells treated with DMSO or 1 µM rucaparib (ruca) at the indicated PD. The average number and proportion of telomere fusion are indicated 
on top of each bar. P values were obtained using Student’s t-test (2 tailed, equal variances, n = 4).
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of rucaparib or olaparib and that were approaching crisis 
(Figure 5C and Supplementary Figure 7). WT HCT116 
cell cultures had a low proportion (7.3%) of early (3.1%) 
and late stage (4.2%) apoptotic cells and PARPi increased 
these levels in WT HCT116 cells (1 µM rucaparib = 
13.5%, 5 µM rucaparib = 16.2%, 1 µM olaparib = 12.5% 
Figure 5: PARPi increases DNA damage checkpoint activation and apoptosis in HCT116 DN-hTERT cells. (A) Cell cycle 
analysis of HCT116 WT DN-hTERT cells as they progress towards telomere crisis (PD59) in the presence of DMSO or 1 µM rucaparib. 
(B) Western blot analysis of a representative experiment from two showing the activation of various DNA damage markers (CHK1-S345, 
p53-S15 and CHK2-T68) in DN-hTERT cells after exposure to 1 µM or 5 µM of rucaparib (Ruca) or olaparib (Ola) for 15 days. HCT116 
WT cells treated with a DNA damaging agent bleomycin (B) or untreated (–) were included as controls. The levels of PARylated proteins 
in these cells were also visualised using an anti-PAR antibody. (C) WT or DN-hTERT HCT116 (PD56) cells were exposed to PARPi for 
15 days, and the level of apoptotic cells were quantified using Annexin-V/propidium iodide (PI) staining. One representative experiment 
from two is shown. 
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and 5 µM olaparib = 23.3%; Supplementary Figure 7). 
As expected, HCT116 DN-hTERT cells (DMSO 
control) approaching crisis exhibited more apoptotic 
cells (9.8% + 7.9% = 17.7%) compared to WT HCT116 
untreated cells (7.3%; Figure 5C). Importantly, both 
rucaparib and olaparib strongly stimulated apoptosis 
in these HCT116 DN-hTERT cells as the total level 
of apoptotic cells (1 µM rucaparib = 29.8%, 5 µM 
rucaparib = 48.4%, 1 µM olaparib = 30.2% and 5 µM 
olaparib = 68.6%) compared to the DMSO control 
(17.7%; Figure 5C) increased. We concluded that PARPi 
enhance DNA damage checkpoint activation and stimulate 
apoptosis in cells experiencing a telomere-induced crisis, 
and that this may account for why PARPi prevent the 
escape from a telomere crisis.
DISCUSSION
Here we provide evidence that PARPi prevent the 
re-immortalization of human tumour cells by inhibiting 
their ability to escape from a telomere-driven crisis. We 
showed that PARPi treated cells accumulate more intra-
chromosomal fusion during crisis. Cells treated with 
PARPi also exhibit enhanced DNA damage checkpoint 
activation and apoptosis. We believe that these phenotypes 
contribute to the ability of PARPi to prevent cells from 
escaping crisis. 
PARPi are considered to act by primarily affecting 
PARP1 because: 1) PARP1 contributes to the majority 
of cellular PARP activity, and 2) PARPi have no effect 
on cellular DNA repair in the absence of PARP1 [33]. 
In addition to interfering with the activity of PARP1, 
PARPi physically trap PARP1 on DNA, which interferes 
with DNA repair and replication [34, 35]. PARPi such as 
rucaparib and olaparib can also inhibit the activities of 
other PARP family members to a lesser extent [36, 37]. 
However, our recent observation that deletion of PARP1 
also strongly prevents HCT116 from escaping a telomere 
crisis [38] suggest that instead of inducing PARP1 trapping 
or inhibiting other PARP family members, PARPi prevent 
escape from crisis mainly by inhibiting PARP1.
PARP1 participates in various pathways of DNA 
repair including DNA single-strand break repair (SSBR), 
double-strand break repair (DSBR), and replication 
fork repair [39]. Interestingly, we previously found that 
deletion of LIG3, a partner of PARP1 in the A-NHEJ 
pathway of DSBR, inhibits escape from a telomere crisis 
[18]. We proposed that a defect in A-NHEJ-induced 
intra-chromosomal fusion could be responsible for 
this observation [18]. However, PARPi do not lead to a 
similar defect in LIG3-induced intra-chromosomal fusion 
suggesting that the inability to escape crisis is likely not 
due to a A-NHEJ defect. In addition to A-NHEJ, LIG3 and 
PARP1 are also implicated together in the same pathway 
of SSBR [40]. Our previous analysis of LIG3 mutants 
show that LIG3 requires its interaction with XRCC1, 
another protein involved in SSBR, to prevent escape from 
crisis, further implicating SSBR as an important factor 
in the escape from crisis [18]. A defect in SSBR could 
lead to accumulation of DNA single-stranded breaks and 
replicative stress in LIG3 deficient or PARPi treated cells. 
We think that this would be particularly harmful in cells 
experiencing telomere crisis, since the telomeric regions 
are poorly protected by the Shelterin complex, especially 
its component TRF1, which is essential for the repair 
of stalled replication forks at telomeres to prevent ATR 
activation [41]. In support of this hypothesis, addition 
of PARPi to cells during crisis strongly activates Chk1 
(Figure 5B), a downstream target of ATR which is induced 
by DNA single-stranded breaks and replicative stress [42]. 
We propose that this severe replicative stress could hyper-
activate the DNA damage response in cells experiencing a 
telomere crisis to selectively killed PARPi treated or LIG3 
deficient cells by stimulating apoptosis. 
Alternatively, it is also possible that PARPi inhibit 
escape from a telomere crisis independently of LIG3. 
PARP1 has been implicated in telomere maintenance 
and PARP1 deficient cells have short telomeres and 
increased telomeric DNA damage [38, 43, 44]. It was 
shown recently that a PARP inhibitor (3-AB) inhibits 
the growth of pancreatic cancer cells treated with a 
telomerase inhibitor by inducing telomere shortening 
through the inhibition of Tankyrases [45]. However, we 
found that treatment of rucaparib did not induce telomere 
shortening in HCT116 DN-hTERT cells (Figure 3D). This 
is likely because rucaparib is a more selective inhibitor of 
PARP1 (compared to 3-AB) which only mildly affect the 
activities of Tankyrases [36]. PARP1 also interacts with 
the Shelterin component TRF2 and is recruited to eroded 
or damaged telomeres to facilitate DNA repair but the 
exact mechanism remains unclear [46, 47]. Recent studies 
show that PARP1 facilitates the recruitment of SLX4 
complex to uncapped telomeres to initiate T loop cleavage 
and homologous recombination [48, 49]. We found that 
rucaparib treated cells cannot repair eroded telomeres 
in HCT116 DN-hTERT cells faithfully, as these cells 
accumulate more intra-chromosomal fusion (Figure 4). We 
speculate that PARPi treatment could reduce localisation 
of SLX4 complex and the homologous recombination 
machinery to eroded telomeres [48], causing a 
homologous recombination defect and an increase in 
sister telomere fusion (observed as intra-chromosomal 
fusion in Figure 4). Alternatively, PARPi could inhibit 
telomere repair by affecting TRF2 in a way that increases 
intra-chromosomal fusion [46]. These proposed defects in 
telomere repair could also contribute to the enhanced DNA 
damage checkpoint activation and apoptosis as observed 
in PARPi treated cells during crisis.
Even though PARP1 deletion in HCT116 DN-
hTERT cells mirrors treatment with olaparib and rucaparib 
by strongly compromising cellular escape from a telomere 
crisis [38], we cannot rule out the possibility that inhibition 
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of other members of PARP protein family by olaparib 
and rucaparib could also contribute to the ability of these 
drugs to inhibit crisis escape. Both olaparib and rucaparib 
could also inhibit PARP2, PARP3, PARP4, PARP10 and 
Tankyrases to a lesser extent than PARP1 [36, 37, 50], 
and these PARP family proteins have been implicated in 
DNA repair, telomere maintenance and mitosis [51–53]. 
It would be interesting to examine whether inhibitors that 
selectively inhibit these proteins also affect cellular escape 
from a telomere crisis [53–56].  
Senescence and crisis represent two distinct 
proliferative lifespan barriers that are governed by 
replicative telomere erosion and they provide a tumour 
suppressive mechanism that must be overcome for 
progression to malignancy [1, 57]. While several drugs, 
called senolytic drugs, that selectively induce apoptosis 
of senescent cells have been identified [58], no drug that 
selectively eliminates cells undergoing a telomere-driven 
crisis have been described. Here we have shown that the 
two PARPi, olaparib and rucaparib, possess this property, 
which we term crisolytic, to allow them to prevent 
cellular escape from telomere crisis and inhibit cell re-
immortalization. 
One potential caveat from our study is that 
our experimental system utilises cancerous cell lines 
(HCT116 and JJN3) that are re-driven into the process 
of telomere crisis, escape and re-immortalisation. 
Thus, it would be important to examine whether 
crisolytic drugs have the same inhibitory effect on 
precancerous cells experiencing a telomere crisis 
in humans. Telomere erosion, dysfunction and 
fusion precede clinical progression in both solid and 
haematological cancers, and can be detected in very 
early stage lesions, providing evidence that a telomere 
crisis occurs early in the progression to malignancy 
[9, 10, 12, 59]. Importantly, telomere length accurately 
predicts the progression of cancer patients with early 
stage disease; for example, patients with CLL Binet stage 
A, who have short dysfunctional telomeres in their CLL 
B-cells, have a poorer prognosis and reduced overall 
survival [11, 14]. It would be interesting to test whether 
PARPi could selectively eliminate crisis cells with short 
dysfunctional telomeres from precancerous lesion or from 
these early stage patients. 
Currently, PARPi are being used either as a 
chemotherapy potentiating agent, or as a monotherapy 
agent, in cancer patients who have cellular defect in 
homologous recombination-mediated DNA repair [23]. 
Several successful clinical trials have resulted in PARPi 
being approved for the treatment of advanced stage 
BRCA1/BRCA2-deficient ovarian cancer patients that 
have been pre-treated with chemotherapy, or who have 
undergone surgery [23]. However, most cancer cells do 
not exhibit these features and there are concerted efforts 
to identify biomarkers to stratify patients that would be 
responsive to PARPi treatment [26]. Our data support 
further preclinical and clinical evaluation of PARPi as a 
potential treatment for cancer patients with tumours that 
exhibit short dysfunctional telomeres, or for the treatment 
of tumours in combination with drugs that induce telomere 
dysfunction (such as inhibitors of telomerase or ligands of 
G quadruplex DNA) as demonstrated by others [45, 47]. 
Importantly, we found that PARPi can selectively eliminate 
cells in crisis that are either p53-positive (HCT116) or 
p53-negative (JJN-3). In the case of p53-negative cells, 
we propose that PARPi stimulates a p53-independent DNA 
damage response and apoptosis in these cells, as JJN-3 
cells are fully capable of activating a robust DNA damage 
response and apoptosis following DNA damage [60]. 
Thus, we propose that PARPi has the potential to target 
a wide range of tumours with dysfunctional telomeres 
regardless of p53 status.
In summary, we provide the first demonstration 
that clinically approved drugs that inhibit PARP1 can 
selectively target and eliminate cells experiencing 
a telomere crisis to prevent cell proliferation and 
immortalisation, suggesting the exciting possibility 
of novel therapeutic avenues for PARPi in the context 
of tumours and pre-cancerous lesions exhibiting short 
dysfunctional telomeres.
MATERIALS AND METHODS
Cell culture and analysis
HCT116 (WT and DN-hTERT) human colorectal 
carcinoma cell lines were as described [18] and grown in 
McCoy’s 5A medium supplemented with 10% fetal calf 
serum (FCS). JJN-3 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
sodium pyruvate (1 mM - Invitrogen), penicillin (100 
Units/ml - Sigma), streptomycin (0.1 mg/ml - Sigma), 
non-essential amino acids (1X - Sigma), FCS (20% v/v 
- Thermo Fisher Scientific) and L-glutamine (2 mM - 
Sigma). Telomere crisis experiments were started from 
clonal cells frozen at different PDs. Cell cycle analyses 
were performed using a two-step cell cycle protocol on 
a NucleoCounter NC-3000™ system (Chemometec). 
Apoptosis was assessed using an Annexin V-FITC 
apoptosis detection kit (eBioscience) on a NucleoCounter 
NC-3000™ system (Chemometec). Rucaparib (S1098-
SEL) and olaparib (S1060-SEL) were purchased from 
Stratech Scientific (UK).
STELA, telomere fusion assay and TRAP
17p and XpYp STELA were performed to 
determine telomere length according to standard 
protocols [18, 30]. Briefly, genomic DNA was isolated 
using standard phenol/chloroform protocol and diluted 
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to 10 ng/μL in 10 mM Tris-HCl (pH 7.5). Ten nanograms 
of DNA were further diluted to 250 pg/μL in a volume 
of 40 μL containing 1 μM Telorette2 linker and 1 mM 
Tris-HCl (pH 7.5). 1 μL of this DNA/Telorette 2 solution 
were subjected to PCR in a 10 μL reaction containing 
0.5 μM telomere-specific primers, 0.5 μM Teltail 
primer and 0.5 U of a 10:1 mixture of Taq (Thermo 
Fisher Scientific) and Pwo polymerase (Roche). The 
PCR products were resolved by 0.5% TAE agarose 
gel electrophoresis and were detected by Southern 
hybridization with a random-primed α-33P-labeled (GE 
Healthcare) TTAGGG repeat probe. Telomere fusion 
assay were performed as described [30, 61]. Briefly, 
50 ng of phenol/chloroform extracted DNA were 
subjected to PCR in a 10 μL reaction containing 0.5 
μM telomere-adjacent primers (XpYpM, 17p6 and 
21q1) and 0.5 U of a 10:1 mixture of Taq (Thermo 
Fisher Scientific) and Pwo polymerase (Roche). 
Fusion molecules were detected by Southern blotting 
as described above and detected with a XpYp or 17p 
telomere-adjacent probes. Telomerase activity was 
quantified using the TRAPeze XL Telomerase detection 
kit (Chemicon International).
Cell lysis and western blot analyses
Cells were lysed in lysis buffer (150 mM NaCl, 
50 mM Tris HCl, 5 mM EDTA, 1% NP40, 3 mM PMSF, 
1/100 protease inhibitor cocktail III [Calbiochem 539134] 
and 1/100 phosphatase inhibitor cocktail II [Calbiochem 
524625]) on ice for 5 min and centrifuged at 20,000g for 
30 min. The proteins in the supernatant were removed 
and quantified using a Pierce Coomassie plus protein 
assay reagent (23236, Thermo Fisher Scientific). For 
western blot analyses, proteins were separated on 7.5% 
Mini-PROTEAN TGX™ precast protein gels (456-1026, 
Biorad), transferred to PVDF membranes (Millipore) 
and probed with either an anti-PAR rabbit polyclonal 
antibody (4336-BPC-100, Trevigen), an anti-phospho-
Chk1 (Ser345) rabbit monoclonal antibody (2348, 
Cell signalling), an anti-phospho-p53 (Ser15) mouse 
monoclonal antibody (9286, Cell signalling), an anti 
phospho-Chk2 (Thr68) rabbit polyclonal antibody (2661, 
Cell signalling) or an anti-actin rabbit polyclonal antibody 
(A2066, Sigma-Aldrich).
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